ANI Pharmaceuticals Inc (ANIP): Total Liabilities
$899.65M
As of 2025-12-31
$896.90M
As of 2026-06-30
+28.7%
3-year compound annual growth
+27.6%
5-year compound annual growth
+21.8%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $899.65M | +5.1% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $855.94M | +91.6% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $446.82M | +6.0% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $421.55M | +2.1% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $412.86M | +55.5% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $265.49M | +8.8% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $244.00M | +4.6% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $233.34M | -1.7% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $237.38M | +54.9% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $153.22M | +22.4% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $125.18M | +4.5% | 2017-03-02, Balance as of period end |
| 2014-12-31 | $119.77M | n/c | 2016-02-23, Balance as of period end |
| 2013-12-31 | $3.54M | -66.6% | 2015-02-23, Balance as of period end |
| 2012-12-31 | $10.59M | -56.9% | 2013-02-28, Balance as of period end |
| 2011-12-31 | $24.56M | -4.1% | 2013-02-28, Balance as of period end |
| 2010-12-31 | $25.62M | n/a | 2012-03-13, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $899.65M | +5.1% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $401.41M | +18.0% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $3.03B | +25.6% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $656.90M | +128.2% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $1.36B | -5.5% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $188.85M | +17.3% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $796.00M | -12.2% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $336.81M | -26.0% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $571.81M | -26.2% |
Compare ANIP, HRMY, IONS, MDGL side by side · Screen every company in Pharmaceutical Preparations ↗